The rising popularity of GLP-1 weight-loss drugs may threaten the supply of insulin, experts warn. Jay Iyer, chief executive of the Access to Medicine Foundation, raised concerns that drug companies are focusing more on weight-loss medications than on essential diabetes treatments. This shift comes as drugs like Novo Nordisk's Ozempic and Eli Lilly's Mounjaro gain popularity in the obesity market.
Key Details
Iyer noted that many people with type 1 diabetes find it hard to access basic insulin. The foundation's report states that diabetes affects about 589 million adults worldwide. Of these, 81% live in low- and middle-income countries (LMICs) such as Pakistan, Egypt, and Jordan. Despite the growing focus on GLP-1 drugs, many of these medications are not registered in LMICs. Where they are available, high prices limit access.
Background
The report warns that companies might leave the insulin market. This would greatly impact those who rely on insulin for their health. Novo Nordisk has already announced plans to phase out some older diabetes products, including insulin pens. Iyer stated, "There is a risk that any of the three – Sanofi, Eli Lilly or Novo Nordisk – could leave the insulin market, and that will be disastrous for supply to insulin, especially for people living with type 1 diabetes."
A potential reduction in insulin supply could affect diabetes treatment costs and availability, especially in low-income areas. Investors may closely watch how pharmaceutical companies handle diabetes medications and GLP-1 products. Look for updates on insulin availability and pricing strategies from major drug firms.
Based on reporting by: theguardian.com